Efficacy, safety, and ARIA risk of anti–β-amyloid antibodies in early Alzheimer’s disease: a systematic review, meta-analysis, and meta-regression
Puntos clave
The research aims to evaluate the efficacy and safety of anti-β-amyloid antibodies in early Alzheimer's disease, including risks related to ARIA.
Conducted systematic review and meta-analysis of existing studies
Analyzed data on efficacy, safety, and ARIA risk
Utilized meta-regression to explore factors influencing outcomes
Anti-β-amyloid antibodies showed significant efficacy in slowing cognitive decline
Safety concerns highlighted an increased risk of ARIA events
Findings underscore the potential benefits and risks associated with treatment
Resumen
http://www.crd.york.ac.uk/prospero identifier is CRD420251071393.
Me gusta
Guardar
Compartir
Me gusta
Guardar
Compartir
Efficacy, safety, and ARIA risk of anti–β-amyloid antibodies in early Alzheimer’s disease: a systematic review, meta-analysis, and meta-regression | Synapse